You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港A異動丨海普瑞A股漲停 H股大漲超28% 注射用H1710獲批開展臨牀試驗
格隆匯 02-19 16:02
海普瑞(9989.HK)今日盤中一度大漲超28%至5.11港元;海普瑞(002399.SZ)臨近午盤漲停,並封住漲停直至收盤。海普瑞昨日晚間公佈,2025年2月17日,深圳市海普瑞藥業集團股份有限公司收到國家藥品監督管理局覈準簽發的《藥物臨牀試驗批準通知書》(受理號:CXHL2401312,通知書編號:2025LP00375),批準注射用H1710開展臨牀試驗。H1710是海普瑞自主研發的候選藥物,公司具有H1710的全球開發及商業化權益。公司臨牀前研究已表明H1710通過抑制乙酰肝素酶的活性和表達表現出抗腫瘤藥理活性,H1710在多種腫瘤動物模型中均展示出顯著的抑瘤作用。截至公告日,於全球範圍內尚無同一分子機制的同類產品上市。(格隆匯)

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account